Overview A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis Status: Terminated Trial end date: 2008-02-01 Target enrollment: Participant gender: Summary To evaluate the efficacy, safety and tolerability of CP-195543 and celecoxib dual therapy in subjects with rheumatoid arthritis Phase: Phase 2 Details Lead Sponsor: PfizerTreatments: CelecoxibMethotrexate